Cargando…

Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry

INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors including alogliptin are categorised as a newer class of oral hypoglycaemic, antidiabetic drugs to suppress the degradation of incretin hormones ((glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) by DPP-4....

Descripción completa

Detalles Bibliográficos
Autores principales:	Inagaki, Nobuya, Ueki, Kohjiro, Tanizawa, Yukio, Watada, Hirotaka, Nakamura, Jiro, Yamada, Yuichiro, Shimomura, Iichiro, Nishimura, Rimei, Yamazaki, Tsutomu, Kadowaki, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166248/ https://www.ncbi.nlm.nih.gov/pubmed/25227623 http://dx.doi.org/10.1136/bmjopen-2013-004760

Ejemplares similares

Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)
por: Ueki, Kohjiro, et al.
Publicado: (2021)

Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial
por: Irie, Yoko, et al.
Publicado: (2018)

Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus
por: Nakamura, Jiro, et al.
Publicado: (2017)

A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes
por: Nishimura, Rimei, et al.
Publicado: (2019)

Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
por: Mita, Tomoya, et al.
Publicado: (2017)

Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study
por: Mita, Tomoya, et al.
Publicado: (2023)

Psychological and behavioural patterns of stigma among patients with type 2 diabetes: a cross-sectional study
por: Kato, Asuka, et al.
Publicado: (2017)

How self-stigma affects patient activation in persons with type 2 diabetes: a cross-sectional study
por: Kato, Asuka, et al.
Publicado: (2020)

Associations between diabetes duration and self-stigma development in Japanese people with type 2 diabetes: a secondary analysis of cross-sectional data
por: Kato, Asuka, et al.
Publicado: (2021)

Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study
por: Nishimura, Rimei, et al.
Publicado: (2019)

Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta‐analysis of randomized controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of two randomized, placebo‐controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2020)

Long‐term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
por: Inagaki, Nobuya, et al.
Publicado: (2011)

Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents in Japanese patients with type 2 diabetes mellitus: a claims database analysis
por: Nishimura, Rimei, et al.
Publicado: (2022)

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2022)

Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND)
por: Tajima, Atsushi, et al.
Publicado: (2022)

Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan—A Protocol
por: Katakami, Naoto, et al.
Publicado: (2017)

Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study
por: Katakami, Naoto, et al.
Publicado: (2020)

Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan
por: Yabe, Daisuke, et al.
Publicado: (2020)

Possible Involvement of Adipose Tissue in Patients With Older Age, Obesity, and Diabetes With SARS-CoV-2 Infection (COVID-19) via GRP78 (BIP/HSPA5): Significance of Hyperinsulinemia Management in COVID-19
por: Shin, Jihoon, et al.
Publicado: (2021)

Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall—a sub-analysis of the UTOPIA trial
por: Katakami, Naoto, et al.
Publicado: (2022)

Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER
por: Takahara, Mitsuyoshi, et al.
Publicado: (2021)

Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus
por: Seino, Yutaka, et al.
Publicado: (2010)

The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Preparation and culture of bone marrow-derived macrophages from mice for functional analysis
por: Toda, Gotaro, et al.
Publicado: (2020)

Dose-Dependent Effect of Sitagliptin on Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Post Hoc Analysis
por: Mita, Tomoya, et al.
Publicado: (2017)

The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation
por: Mita, Tomoya, et al.
Publicado: (2017)

Changes in carotid intima‐media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima‐Media Thickness Evaluation
por: Mita, Tomoya, et al.
Publicado: (2017)

Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity
por: Sasaki, Akira, et al.
Publicado: (2021)

Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)

Effect of a Multifactorial Intervention on Fracture in Patients With Type 2 Diabetes: Subanalysis of the J-DOIT3 Study
por: Sasako, Takayoshi, et al.
Publicado: (2021)

Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study
por: Takeda, Hiroshi, et al.
Publicado: (2016)

The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis
por: Mita, Tomoya, et al.
Publicado: (2017)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity
por: Okada-Iwabu, Miki, et al.
Publicado: (2015)

Chronological Analysis With Fluorescent Timer Reveals Unique Features of Newly Generated β-Cells
por: Miyatsuka, Takeshi, et al.
Publicado: (2014)

Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE)
por: Katakami, Naoto, et al.
Publicado: (2018)

Cluster‐randomized trial to improve the quality of diabetes management: The study for the efficacy assessment of the standard diabetes manual (SEAS‐DM)
por: Noto, Hiroshi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_thesiomknjorbflmtkeprh06lo